A malignant renal mass is a cancer of the kidney. Renal cell carcinoma (RCC) is by far the most common type, accounting for approximately 90% of kidney cancers and nearly 80,000 new diagnoses per year in the United States. Increasing use of abdominal imaging means the majority of kidney cancers today are found incidentally at small sizes and early stages — when 5-year survival after surgical treatment exceeds 95% for localized disease. MRI plays a central role in distinguishing kidney cancer from benign masses, staging disease extent, and planning surgical or ablative treatment.
The most important first step when any kidney mass is identified is accurate characterization to distinguish malignancy from the many benign renal masses — particularly angiomyolipoma, oncocytoma, and complex cysts — that require no surgery. MRI with its multiparametric capability performs this distinction better than any other modality. The adrenal glands, which sit directly atop the kidneys, are evaluated on every renal MRI — adrenal metastases from RCC and primary adrenal masses are important concurrent findings. Renal vein and inferior vena cava tumor thrombus extension — a critical staging finding that determines surgical approach — is precisely characterized on MRI.
Causes
Genetic and environmental risk factors.
The most important molecular driver of clear cell RCC — the dominant subtype — is inactivation of the VHL (von Hippel-Lindau) tumor suppressor gene on chromosome 3p, which occurs in approximately 75–80% of clear cell RCCs, both in sporadic cases and in von Hippel-Lindau hereditary syndrome. VHL inactivation leads to constitutive activation of the HIF (hypoxia-inducible factor) pathway, driving overexpression of VEGF and promoting tumor angiogenesis — the mechanistic basis for the efficacy of anti-VEGF targeted therapies in RCC. Cigarette smoking doubles the risk of RCC and is the most prevalent modifiable risk factor. Obesity increases RCC risk through multiple mechanisms including hypertension, insulin resistance, and altered adipokine signaling. Hypertension — independent of medications used to treat it — is an established RCC risk factor. Acquired cystic kidney disease from long-term dialysis produces markedly elevated RCC risk, estimated at 3–6 times the general population rate.
Inherited syndromes.
Approximately 3–5% of RCCs are hereditary. Von Hippel-Lindau (VHL) disease causes multiple bilateral clear cell RCCs alongside hemangioblastomas of the brain and spine, retinal angiomas, pheochromocytomas, and pancreatic cysts. Hereditary papillary RCC (HPRCC) is caused by MET proto-oncogene mutations and produces bilateral multifocal papillary type 1 RCCs. Birt-Hogg-Dubé syndrome (FLCN gene mutations) produces hybrid oncocytic/chromophobe RCCs alongside pulmonary cysts and fibrofolliculomas. Hereditary leiomyomatosis and renal cell cancer (HLRCC, FH gene) causes highly aggressive papillary type 2 RCC alongside uterine and cutaneous leiomyomas. All patients with bilateral, multifocal, or early-onset RCC should be referred for genetic counseling.
Symptoms
The majority of kidney cancers in the modern imaging era are asymptomatic at diagnosis — found incidentally on CT or MRI performed for back pain, abdominal symptoms, or general health screening. The classic triad of gross hematuria, flank pain, and a palpable abdominal mass — the "too late triad" — is now seen in fewer than 10% of patients and typically indicates locally advanced or metastatic disease. Hematuria is the most actionable single symptom — any episode of painless gross hematuria in an adult requires urologic evaluation including imaging. Constitutional symptoms including fatigue, weight loss, night sweats, and low-grade fever may indicate advanced disease or paraneoplastic syndromes. RCC has the most diverse repertoire of paraneoplastic syndromes of any solid tumor: polycythemia (from ectopic erythropoietin production), hypercalcemia (from PTHrP), hypertension (from renin secretion), Stauffer syndrome (non-metastatic hepatic dysfunction — reversible after nephrectomy), and amyloidosis are all recognized manifestations.
Diagnosis
Renal masses are most commonly initially detected on ultrasound or contrast-enhanced CT. CT provides the initial staging assessment and identifies lymph node involvement, contralateral kidney status, and adrenal and hepatic metastases. Renal vein and IVC involvement may be visible on CT but is optimally characterized on MRI.
An MRI of the abdomen is the most accurate imaging study for renal mass characterization and surgical planning. Clear cell RCC — the dominant subtype — is characteristically hypervascular: it shows bright arterial enhancement on the corticomedullary phase MRI that drops to near-isointensity on the nephrographic phase ("washout") — a pattern that reflects the VHL-driven VEGF overexpression and tumor vascularity. Signal drop on opposed-phase chemical shift imaging (intracellular lipid) further supports clear cell RCC, as the intratumoral microscopic fat differs from the macroscopic fat of AML. Papillary RCC is characteristically T2-hypointense (dark) with minimal enhancement — its hypovascular nature distinguishes it from clear cell RCC. Chromophobe RCC enhances homogeneously and may show a central scar. Diffusion-weighted imaging (DWI) shows restricted diffusion (low ADC values) in malignant solid masses. The critical surgical planning finding is renal vein and inferior vena cava tumor thrombus — MRI with MR venography delineates thrombus extent precisely, distinguishing tumor thrombus (which enhances on gadolinium sequences) from bland thrombus (which does not), and determining whether the thrombus extends above or below the hepatic veins — a determination that changes surgical complexity and approach dramatically.
Classification
Renal malignancies are classified by histologic subtype and TNM stage.
- Clear cell RCC (~75%): Most common and most studied subtype. VHL-driven, hypervascular, with bright corticomedullary enhancement. Highest response rates to VEGF-targeted therapy and immunotherapy. Most hereditary RCC syndromes produce clear cell histology.
- Papillary RCC (~15%): Type 1 (HPRCC-associated, indolent, MET-driven) and Type 2 (HLRCC-associated, aggressive, FH-driven). Hypovascular and T2-hypointense on MRI. Often multifocal and bilateral in hereditary forms.
- Chromophobe RCC (~5%): Generally less aggressive than clear cell. Associated with Birt-Hogg-Dubé syndrome. Overlaps histologically with oncocytoma — the two may coexist in the same kidney ("hybrid oncocytic-chromophobe tumor").
- Collecting duct and medullary carcinoma: Rare and highly aggressive. Medullary carcinoma is almost exclusively associated with sickle cell trait. Poor prognosis regardless of stage.
- Urothelial carcinoma of the renal pelvis: Arises from the urothelium lining the collecting system rather than renal parenchyma. Associated with smoking, aristolochic acid (herbal tea exposure), and Lynch syndrome. Presents with hematuria and is staged and treated differently from parenchymal RCC.
- Wilms tumor (nephroblastoma): Most common kidney cancer in children under 5. Treated with combined surgery, chemotherapy, and sometimes radiation with excellent overall survival.
TNM staging: Stage I (?7 cm, confined to kidney), Stage II (>7 cm, confined to kidney), Stage III (renal vein/IVC thrombus, perinephric fat invasion, regional lymph nodes), Stage IV (adrenal invasion or distant metastases). Five-year survival: Stage I >95%, Stage II ~80%, Stage III ~55%, Stage IV ~12%.
Treatments
Treatment is guided by tumor size, histologic subtype, TNM stage, renal function, and patient fitness.
Partial nephrectomy: Nephron-sparing surgery — removing only the tumor with a rim of normal tissue while preserving the remaining kidney — is the standard of care for Stage I–II RCC whenever technically feasible. Robotic-assisted partial nephrectomy has largely supplanted open surgery at high-volume centers, offering equivalent oncologic outcomes with shorter recovery. MRI preoperative mapping defines tumor relationships to the collecting system, renal sinus fat, and hilar vessels. Five-year recurrence-free survival after partial nephrectomy for Stage I RCC exceeds 95%.
Radical nephrectomy.
Removal of the entire kidney with perinephric fat and regional lymph nodes is performed for large tumors (>7 cm), tumors in locations precluding partial nephrectomy, or when renal vein/IVC thrombus requires complex reconstruction. For IVC thrombus extending above the hepatic veins or into the right atrium, cardiac surgery with cardiopulmonary bypass may be required for safe thrombus extraction.
Thermal ablation.
Radiofrequency ablation (RFA) and cryoablation — delivered percutaneously under CT or MRI guidance — are effective treatments for RCC lesions under 3 cm in patients who cannot tolerate surgery due to comorbidities, impaired renal function, or who have a solitary kidney. MRI is used to confirm complete ablation (absence of residual enhancement) and monitor for local recurrence. Five-year local recurrence rates after ablation for T1a tumors are approximately 5–8%.
Active surveillance.
Small renal masses (<2 cm, and selected 2–3 cm tumors in older patients with significant comorbidities) may be safely observed with serial MRI at 3–6 month intervals initially, then annually. Growth rate less than 5 mm/year is reassuring. The majority of small incidental renal masses grow slowly and may never require intervention during a patient's lifetime — active surveillance avoids the risks of surgery in patients for whom the lifetime risk of intervention exceeds the benefit.
Systemic therapy for advanced disease.
Metastatic RCC has been transformed by the combination of immune checkpoint inhibitors and VEGF-targeted agents. Nivolumab plus ipilimumab (dual checkpoint blockade) and pembrolizumab plus axitinib or lenvatinib are current first-line standard regimens for intermediate/poor-risk metastatic clear cell RCC, producing complete response rates of 10–15% and median overall survival exceeding 4 years in favorable-risk patients — a dramatic improvement over the historical median of 12–18 months with monotherapy. Sunitinib, pazopanib, and cabozantinib are VEGF-receptor TKI options. Belzutifan — a HIF-2? inhibitor — is approved for VHL disease-associated RCC and shows promise in sporadic clear cell RCC.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Abdomen MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.